Home LiteratureArticle Details
PMID: 20068082 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Dai Y, Grant S

Abstract

The DNA damage response (DDR) represents a complex network of multiple signaling pathways involving cell cycle checkpoints, DNA repair, transcriptional programs, and apoptosis, through which cells maintain genomic integrity following various endogenous (metabolic) or environmental stresses. In cancer treatment, the DDR occurs in response to various genotoxic insults by diverse cytotoxic agents and radiation, representing an important mechanism limiting chemotherapeutic and radiotherapeutic efficacy. This has prompted the development of agents targeting DDR signaling pathways, particularly checkpoint kinase 1 (Chk1), which contributes to all currently defined cell cycle checkpoints, including G1/S, intra-S-phase, G2/M, and the mitotic spindle checkpoint. Although numerous agents have been developed with the primary goal of enhancing the activity of DNA-damaging agents or radiation, the therapeutic outcome of this strategy remains to be determined. Recently, new insights into DDR signaling pathways support the notion that Chk1 represents a core component central to the entire DDR, including direct involvement in DNA repair and apoptotic events in addition to checkpoint regulation. Together, these new insights into the role of Chk1 in the DDR machinery could provide an opportunity for novel approaches to the development of Chk1 inhibitor strategies.

MeSH Terms
Antineoplastic Agents/therapeutic use Checkpoint Kinase 1 DNA Damage/genetics,physiology DNA Repair/genetics Enzyme Activation/genetics Humans Models, Biological Neoplasms/drug therapy,genetics,metabolism Protein Kinase Inhibitors/therapeutic use Protein Kinases/genetics,metabolism,physiology Signal Transduction/genetics
Chemicals
Antineoplastic Agents Protein Kinase Inhibitors Protein Kinases CHEK1 protein, human Checkpoint Kinase 1
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Dai Yun
Department of Medicine, Institute for Molecular Medicine, and Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia 23298, USA.
Grant Steven
References (59)
59 references, click to expand
  1. The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer?
    Cancer Biol Ther. 2009 Aug;8(15):1433-9 PMID: 19574738
  2. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Mol Pharmacol. 2009 Jan;75(1):124-33 PMID: 18820127
  3. Regulation of chk1.
    Cell Div. 2009 Apr 29;4:8 PMID: 19400965
  4. Cell-cycle checkpoints and cancer.
    Nature. 2004 Nov 18;432(7015):316-23 PMID: 15549093
  5. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.
    Cancer Res. 2007 Feb 1;67(3):1046-53 PMID: 17283137
  6. Targeting DNA checkpoint kinases in cancer therapy.
    Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S16-22 PMID: 14508077
  7. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
    Cell Cycle. 2007 Jan 1;6(1):104-10 PMID: 17245119
  8. Regulation of DNA repair throughout the cell cycle.
    Nat Rev Mol Cell Biol. 2008 Apr;9(4):297-308 PMID: 18285803
  9. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction.
    Nat Rev Cancer. 2007 Nov;7(11):861-9 PMID: 17943134
  10. Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1).
    Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11964-9 PMID: 16873548
  11. Cleavage-mediated activation of Chk1 during apoptosis.
    J Biol Chem. 2008 Sep 12;283(37):25485-25491 PMID: 18550533
  12. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
    Mol Cell Biol. 2005 May;25(9):3553-62 PMID: 15831461
  13. Reconstitution of a human ATR-mediated checkpoint response to damaged DNA.
    Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13301-6 PMID: 17686975
  14. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
    Blood. 2007 May 15;109(10):4415-23 PMID: 17264303
  15. A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint.
    Genes Dev. 2009 Jun 1;23(11):1364-77 PMID: 19487575
  16. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
    Clin Cancer Res. 2008 Jul 1;14(13):4032-7 PMID: 18593978
  17. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.
    Mol Cancer Ther. 2009 Oct;8(10):2894-902 PMID: 19808981
  18. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):591-602 PMID: 17255282
  19. Targeting checkpoint kinase 1 in cancer therapeutics.
    Clin Cancer Res. 2007 Apr 1;13(7):1955-60 PMID: 17404075
  20. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
    Mol Cancer Ther. 2008 Sep;7(9):2955-66 PMID: 18790776
  21. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.
    Mol Cancer Ther. 2007 Jan;6(1):147-53 PMID: 17237275
  22. Human Tim/Timeless-interacting protein, Tipin, is required for efficient progression of S phase and DNA replication checkpoint.
    J Biol Chem. 2007 Jan 26;282(4):2729-40 PMID: 17102137
  23. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
    PLoS Genet. 2009 Jan;5(1):e1000324 PMID: 19119425
  24. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
    Mol Cancer Ther. 2009 Jan;8(1):45-54 PMID: 19139112
  25. Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex.
    J Biol Chem. 2003 Aug 8;278(32):29940-7 PMID: 12756247
  26. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.
    Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20752-7 PMID: 19091954
  27. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks.
    Nat Cell Biol. 2006 Jan;8(1):37-45 PMID: 16327781
  28. Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis.
    Mol Cell Biol. 2002 Oct;22(20):7226-41 PMID: 12242299
  29. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
    Mol Cancer. 2009 Jun 08;8:34 PMID: 19500427
  30. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
    Cancer Res. 2001 Jul 1;61(13):5106-15 PMID: 11431348
  31. ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function.
    Oncogene. 2006 Feb 23;25(8):1153-64 PMID: 16186792
  32. Chk1 is required for spindle checkpoint function.
    Dev Cell. 2007 Feb;12(2):247-60 PMID: 17276342
  33. DNA damage checkpoints: from initiation to recovery or adaptation.
    Curr Opin Cell Biol. 2007 Apr;19(2):238-45 PMID: 17303408
  34. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
    Clin Cancer Res. 2009 Jul 15;15(14):4630-40 PMID: 19584159
  35. All eukaryotes: before turning off G1-S transcription, please check your DNA.
    Cell Cycle. 2009 Jan 15;8(2):214-7 PMID: 19158488
  36. The S phase checkpoint: when the crowd meets at the fork.
    Semin Cell Dev Biol. 2005 Jun;16(3):355-68 PMID: 15840444
  37. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
    Mol Cancer Ther. 2008 Aug;7(8):2394-404 PMID: 18723486
  38. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3.
    Cell. 2008 May 30;133(5):864-77 PMID: 18510930
  39. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
    Cancer Res. 2001 Nov 15;61(22):8211-7 PMID: 11719452
  40. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways.
    Nat Genet. 2002 Mar;30(3):290-4 PMID: 11850621
  41. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation.
    Mol Cell Biol. 2007 Apr;27(7):2572-81 PMID: 17242188
  42. The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis.
    Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5159-64 PMID: 19289837
  43. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors.
    Mol Cancer. 2009 Apr 16;8:24 PMID: 19371427
  44. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
    Clin Cancer Res. 2008 Oct 15;14(20):6704-11 PMID: 18927314
  45. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
    J Clin Oncol. 2005 Mar 20;23(9):1875-84 PMID: 15699481
  46. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
    Br J Cancer. 2008 Feb 12;98(3):523-8 PMID: 18231106
  47. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.
    BMC Cancer. 2006 Dec 19;6:292 PMID: 17177986
  48. Tipin and Timeless form a mutually protective complex required for genotoxic stress resistance and checkpoint function.
    Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18143-7 PMID: 17116885
  49. Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity.
    Oncogene. 2009 Jun 18;28(24):2314-23 PMID: 19421147
  50. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
    Blood. 2008 Sep 15;112(6):2439-49 PMID: 18614762
  51. Dual functions of DNA replication forks in checkpoint signaling and PCNA ubiquitination.
    Cell Cycle. 2009 Jan 15;8(2):191-4 PMID: 19158510
  52. Chk1 and Chk2 kinases in checkpoint control and cancer.
    Cancer Cell. 2003 May;3(5):421-9 PMID: 12781359
  53. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation.
    Cancer Res. 2004 Dec 15;64(24):9035-40 PMID: 15604269
  54. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
    J Biol Chem. 2003 Dec 26;278(52):52572-7 PMID: 14570880
  55. The Chk1-mediated S-phase checkpoint targets initiation factor Cdc45 via a Cdc25A/Cdk2-independent mechanism.
    J Biol Chem. 2006 Oct 13;281(41):30631-44 PMID: 16912045
  56. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A.
    Cancer Cell. 2003 Mar;3(3):247-58 PMID: 12676583
  57. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.
    Nat Cell Biol. 2005 Feb;7(2):195-201 PMID: 15665856
  58. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway.
    Mol Cell Biol. 2007 Apr;27(8):3098-108 PMID: 17296736
  59. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression.
    Cell. 2008 Jan 25;132(2):221-32 PMID: 18243098
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1557-3265
Published
2010-01-15
Epub
2010-00-12
Pages
376-83
Language
English
Region
United States
NLM ID
9502500
PMCID
PMC2939735
Subset
IM
Grants
NCI NIH HHS · R01 CA093738-07 · United States
NCI NIH HHS · 1P50 CA130805 · United States
NCI NIH HHS · R21 CA115260-02 · United States
NCI NIH HHS · R01 CA063753 · United States
NCI NIH HHS · R01 CA100866-05A2 · United States
NCI NIH HHS · R01 CA093738 · United States
NCI NIH HHS · CA100866 · United States
NCI NIH HHS · R01 CA063753-14 · United States
NCI NIH HHS · P50 CA130805 · United States
NCI NIH HHS · CA93738 · United States
NCI NIH HHS · R21 CA115260 · United States
NCI NIH HHS · CA63753 · United States
NCI NIH HHS · R21 CA137823 · United States
NCI NIH HHS · R21 CA137823-01A1 · United States
NCI NIH HHS · R01 CA100866 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com